GAMMA Investing LLC Purchases New Position in RedHill Biopharma Ltd. (NASDAQ:RDHL)

GAMMA Investing LLC acquired a new stake in shares of RedHill Biopharma Ltd. (NASDAQ:RDHL) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 5,089 shares of the biotechnology company’s stock, valued at approximately $32,000. GAMMA Investing LLC owned approximately 0.40% of RedHill Biopharma as of its most recent filing with the SEC.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on shares of RedHill Biopharma in a research note on Wednesday, January 8th. They set a “hold” rating on the stock.

RedHill Biopharma Trading Down 1.1 %

NASDAQ RDHL opened at $5.51 on Wednesday. The stock has a market cap of $7.06 million, a price-to-earnings ratio of -0.55 and a beta of 3.69. RedHill Biopharma Ltd. has a 12 month low of $5.41 and a 12 month high of $31.50. The company’s 50 day moving average is $7.10 and its two-hundred day moving average is $70.00.

About RedHill Biopharma

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.